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Kamińska, A.; Avitabile, T.;
Wełniak-Kaminska, M.; Grieb, P.; et al.
Tryptophan Pathway Abnormalities
in a Murine Model of Hereditary
Glaucoma. Int. J. Mol. Sci. 2021, 22,
1039. https://doi.org/doi:10.3390/
ijms22031039
Academic Editor: Ciriana Orabona
Received: 2 December 2020
Accepted: 19 January 2021
Published: 21 January 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland;
mfiedorowicz@imdik.pan.pl (M.F.); marlenak@imdik.pan.pl (M.W.-K.); pgrieb@imdik.pan.pl (P.G.)
2 Department of General Ophthalmology, Medical University of Lublin, 20-079 Lublin, Poland;
tomekchor@wp.pl (T.C.); dominika.nowakowska85@gmail.com (D.N.); kamwer@gmail.com (K.W.);
robertrejdak@yahoo.com (R.R.)
3 Department of Experimental and Clinical Pharmacology, Medical University of Lublin, 20-079 Lublin, Poland;
turskiwa@op.pl (W.A.T.); tomek94@poczta.onet.pl (T.K.)
4 Faculty of Medical Sciences, Collegium Medicum, Cardinal Stefan Wyszyński University,
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Abstract: Background: It has been shown that a possible pathogenetic mechanism of neurodegenera-
tion in the mouse model of glaucoma (DBA/2J) may be an alteration of kynurenic acid (KYNA) in
the retina. This study aimed to verify the hypothesis that alterations of tryptophan (TRP) metabolism
in DBA/2J mice is not limited to the retina. Methods: Samples of the retinal tissue and serum were
collected from DBA/2J mice (6 and 10 months old) and control C57Bl/6 mice of the same age. The
concentration of TRP, KYNA, kynurenine (KYN), and 3-hydroxykynurenine (3OH-K) was measured
by HPLC. The activity of indoleamine 2,3-dioxygenase (IDO) was also determined as a KYN/TRP
ratio. Results: TRP, KYNA, L-KYN, and 3OH-K concentration were significantly lower in the retinas
of DBA/2J mice than in C57Bl/6 mice. 3OH-K concentration was higher in older mice in both strains.
Serum TRP, L-KYN, and KYNA concentrations were lower in DBA/2J than in age-matched controls.
However, serum IDO activity did not differ significantly between compared groups and strains.
Conclusions: Alterations of the TRP pathway seem not to be limited to the retina in the murine model
of hereditary glaucoma.
Keywords: glaucoma; kynurenine pathway; DBA/2J; retina
1. Introduction
Glaucoma is the most frequent cause of irreversible blindness worldwide [1–3]. It is
associated with retinal ganglion cell (RGC) degeneration and loss. Moreover, neurodegen-
eration in glaucoma is not limited to RGCs and their axons, forming the optic nerve, but
seems to affect numerous brain structures, particularly vision-related brain structures [2–7].
The mechanism of neurodegeneration in glaucoma is not sufficiently elucidated, and in
particular, the mechanisms of this so-called extraretinal neurodegeneration are poorly
understood [7,8].
One of the possible mechanisms involved in glaucomatous neurodegeneration is acti-
vation of the major metabolic pathway for tryptophan (TRP) metabolism, the kynurenine
pathway (KP), or shift in the balance between the three KP branches metabolizing the
central KP metabolite, kynurenine (KYN). Some of the KP metabolites are known to display
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neurotoxic (e.g., quinolinic acid, QUIN; the agonist of the NMDA receptor [9]) or neuro-
protective properties (e.g., kynurenic acid, KYNA; the antagonist of the NMDA and the
alpha-7 nicotinic acetylcholine receptors [10,11]). KP is also essential for energy metabolism.
Additionally, it may contribute to the modulation of the immune response [12].
Retinal KYNA levels were shown to be elevated in response to RGC damage [13]. As
we recently have shown, the dynamics of KP alteration due to RGC damage is different
depending on the nature of the insult (or animal model of RGC loss used) [14]. Importantly,
recent results suggest that manipulation in KP enzymes activity may exert neuroprotective
effects on RGC [15].
It would be highly important to evaluate KP metabolites in a glaucoma model that
would resemble the situation in chronic, age-related disease, like the majority of glaucoma
cases. Such a model would also enable tracking systemic changes in KP metabolites levels,
not only in the retina. The DBA/2J murine strain mimics pigmentary glaucoma. In this
strain, glaucomatous alteration develops slowly with age and is not restricted to the retina
but also affects other vision-related brain structures [16]. DBA/2J mice carry mutations
in tyrosinase-related protein 1 gene (Tyrp1isa) and glycoprotein nonmetastatic melanoma
protein B gene (GpnmbR150X). These mutations induce anterior segment anomalies such as
iris atrophy, pigment dispersion syndrome, and anterior synechia that result in disturbances
in the aqueous humor outflow at the trabecular meshwork, IOP elevation [17–20] as well
as RGCs loss and alterations of the ocular morphology [17,21]. They also develop age-
related failure of the anterograde axonal transport within the RGC axons [22,23]. We have
previously shown that KP is affected in the course of spontaneous retinal degeneration in
this glaucoma model [24,25]. However, no data are available on the systemic changes in
TRP metabolism and KP in the course of spontaneous glaucoma in these mice.
This study aimed to verify the hypothesis that alterations of TRP metabolism in
DBA/2J mice are not limited to the retina but will also be detectable in the serum.
2. Results
2.1. Retina
In 10-month-old DBA/2J mice, magnetic resonance imaging (MRI) revealed deepening
of the anterior chamber (Figure 1). Retina visualization after systemic administration of
manganese chloride also showed optic disc cupping (Figure 1B, arrowhead) that was not
visible in C57Bl/6 mice (Figure 1A).
 
Figure 1. Representative T1-weighted magnetic resonance images of the eyes in 10-month-old
C57BL/6 (A) and DBA/2J (B) mice 24 h after administration of a manganese contrast agent. The
black arrowhead indicates the optic disc cupping (black arrowhead). White arrow—enlarged anterior
chamber of the eye in DBA/2J.
2.1.1. Kynurenic Acid
Both in 6-month and 10-month-old DBA/2J mice, a significantly lower concentra-
tion of retinal KYNA was observed (12.95 and 13.55 pmol/mg) than in C57BL/6 mice.
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(21.01 pmo/mg, p < 0.001 and 24.27 pmol/mg. p < 0.001). No statistically significant
differences were observed between 6- and 10-month-old DBA/2J mice (Figure 2).
 
Figure 2. The levels of tryptophan (TRP), L-kynurenine (L-KYN), kynurenic acid (KYNA), and 3-hydroxykynurenine
(3OH-K) in the retinas of C57BL/6 and DBA/2J mice. Values are expressed as a percentage of TRP, L-KYN, KYNA, or
3-OH-K concentrations in samples from 6-month-old C57Bl/6 mice. # p < 0.05, ### p < 0.001 DBA2J vs. C57Bl/6; * p < 0.05,
***p < 0.001 10 months vs. 6 months.
2.1.2. 3-Hydroxykynurenine
Levels of 3OH-K were higher both in 6- and 10-month-old DBA/2J mice (4.42 and
3.91 pmol/mg, respectively) than in C57BL/6 mice (1.86 pmol/mg, p < 0.001 and
1.61 pmol/mg, p < 0.05, respectively). Both in DBA/2J and C57BL/6 mice, concentra-
tions in 6 months old animals were significantly lower than in 10 months (p < 0.01 and
p < 0.05, respectively) (Figure 2).
2.1.3. Tryptophan
Retinal TRP concentration observed in 6 months old DBA/2J mice (19.13 pmol/mg)
was significantly lower than in C57BL/6 mice (37.23 pmol/mg, p < 0.001). The difference
in concentration in 10-month-old mice was not statistically significant between the two
groups (24.50 pmol/mg vs. 21.84 pmol/mg; Figure 2).
2.1.4. L-Kynurenine
Retinal levels of L-KYN both in 6- and 10-month-old DBA/2J mice (1.54 and 1.30 pmol/kg)
were significantly lower than in C57BL/6 mice (2.33 pmol/mg, p < 0.05 and 3.08 pmol/mg,
p < 0.05). No statistically significant differences were observed between 6- and 10-month-old
DBA/2J mice (Figure 2).
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2.2. Serum
2.2.1. Kynurenic acid
Both 6-month and 10-month-old DBA/2J mice had a significantly lower concentration
of KYNA in serum (5.15 and 6.66 pmol/mL) when compared to C57BL/6 control mice
(11.96 pmol/mL, p < 0.001 and 11.66 pmol/mL, p < 0.05). No statistically significant
differences were observed between 6- and 10-month-old DBA/2J mice (Figure 3).
Figure 3. The levels of tryptophan (TRP), L-kynurenine (L-KYN), kynurenic acid (KYNA), and 3-hydroxykynurenine
(3OH-K) in the serum of C57BL/6 and DBA/2J mice. Values are expressed as a percentage of TRP, L-KYN, KYNA, or
3-OH-K concentrations in samples from 6-month-old C57Bl/6 mice. # p < 0.05, ### p < 0.001 DBA2J vs. C57Bl/6; * p < 0.05,
***p < 0.001 10 months vs. 6 months.
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2.2.2. 3-Hydroxykynurenine
No statistically significant difference was observed in 3OH-K serum concentration
in 6-month-old DBA/2J mice (14.38 pmol/mL) compared to 6-month-old C57BL/6 mice
(12.91 pmol/mL). In contrast, in 10-month-old DBA/2J mice, serum concentration was sig-
nificantly higher (13.95 pmol/mL) than in C57BL/6 mice of the same age (12.33 pmol/mL,
p < 0.05). A significantly lower 3OH-K concentration was observed in 10-month-old
DBA/2J mice than in 6-month-old animals of this strain (p < 0.05, Figure 3).
2.2.3. Tryptophan
In both 6- and 10-month-old DBA/2J mice serum level of TRP (673.13 and 598.89 pmol/mL)
was lower than in C57BL/6 mice (805.76 pmol/mL, p < 0.001 and 872.74 pmol/mL, p < 0.05).
Concentration in the serum of 10-month-old DBA/2J mice was significantly lower (p < 0.01)
than in 6-month-old mice (Figure 3).
2.2.4. L-Kynurenine
Both 6-month and 10-month-old DBA/2J mice had a significantly lower concentration
of L-KYN in serum (138.09 and 139.23 pmol/mL) when compared to C57BL/6 control mice
(105.49 pmol/mL, p < 0.001 and 100.34 pmol/mL, p < 0.05).
2.3. IDO activity
No significant differences in IDO activity were observed between 6- and 10-month-old
DBA/2J and C57BL/6 mice both in the retina (Figure 4) and serum (Figure 5).
Figure 4. Indoleamine 2,3 dioxygenase (IDO) activity was expressed as a kynurenine/tryptophan
ratio in the retina of C57BL/6 and DBA/2J mice.
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Figure 5. Indoleamine 2,3 dioxygenase (IDO) activity was expressed as a kynurenine/tryptophan
ratio in the serum of C57BL/6 and DBA/2J mice.
3. Discussion
DBA/2J mice are widely used as a glaucoma model, presenting secondary angle-
closure glaucoma caused by pigment debris deposition and blockage of the aqueous fluid
outflow that develops spontaneously in an age-dependent manner [24]. In these mice, we
evaluated KP metabolites concentrations, both in the retina and in the serum. We showed
that the pattern of differences between the control mice and glaucoma model as well
age-dependent differences were generally similar in the retina and serum. Interestingly, no
age-dependent 3OH-K elevation was observed in the serum in contrast to the retinas.
DBA/2J mice develop several age-related pathologies. IOP elevation in these mice
is observed around the 6th month of age, and after the 12th month of age, IOP starts to
decrease. In addition, alterations in ocular morphology like the elongation of the eyeball,
deepening of the anterior chamber, or increased iridocorneal angle begin around the
6th month [26–31]. At the 10th month, these alterations were already clearly visible in
the present study. In this study, we also noticed signs of retinal neurodegeneration in
10-month-old mice, i.e., optic disc cupping.
Disease progression in the DBA/2J glaucoma model is associated with RGC degen-
eration and loss at the later pathology stages. Apoptotic RGCs were found as early as in
3-month-old animals [21]. However, RGC density was shown to remain relatively stable
up to 12 months of age [32], despite a dramatic decrease in visual acuity demonstrated in
11-month-old animals [33]. Therefore, it seems that RGC degeneration rather than loss and
axonal transport failure contribute to the pathological changes in the retina and the optic
nerve in these mice at moderately advanced stages of the disease [22].
Some data indicate that pathological processes start earlier than noticeable IOP eleva-
tion, even as early as in 3-month-old animals [22,34]. Nevertheless, DBA/2J performance
in visual tasks seems similar to C57BL/6 mice at 6 months and significantly decreased
when the mice are older [33,35]. Therefore, we selected two timepoints that seem repre-
sentative for the pathology in this glaucoma model – mice at the early stage of disease
(6-month-old) and with moderately advanced glaucoma (10-month-old). As controls for
the murine model of glaucoma, we used C57BL/6J mice. This strain is frequently used as a
control for DBA/2J mice in experimental ophthalmology studies [16,22,27,35]. C57BL/6
mice develop only mild age-related IOP elevation and do not normally display detectable
abnormalities in the ocular morphology [22,27,36]. We did not observe any abnormalities
Int. J. Mol. Sci. 2021, 22, 1039 7 of 12
reported to sporadically develop in these mice [37] like microphthalmia/anophthalmia or
corneal opacity.
Alterations in KP may contribute to retinal degeneration in DBA/2J mice. The levels
of KYNA, the neuroprotective KP metabolite, were lower in the retinas of DBA/2J mice
than in control retinas; that result is in accordance with our previous results [24]. However,
in this study, we did not detect an age-related decrease in KYNA concentration in these
mice. It may be an effect of slightly earlier timepoints proposed in the current study. Our
previous results also demonstrated changes in retinal KYNA in two surgical models of
glaucoma. A complex response was noted after NMDA administration (a transient increase
2 days after NMDA injection and then a decrease) and a massive decrease of retinal KYNA
concentration due to partial optic nerve crush [14]. The decrease in KYNA concentration
observed in this study seems to be an effect of KP failure. Not surprisingly, we did not
observe a transient increase in KYNA levels that could reflect endogenous anti-excitotoxic
defense mechanisms. We believe that the present experimental setup, a slowly progressing
model of hereditary glaucoma, might be close to the situation in clinics.
A lower level KYNA, as well as TRP and L-KYN, might result from decreased levels of
these metabolites in the serum that we noted in this study. However, KYNA was thought
to cross the blood-retina barrier (BRB) hardly [38]; in DBA/2J mice, intravenous adminis-
tration of KYNA resulted in RGC neuroprotection, which can suggest BRB permeability in
DBA/2J mice due to decoupling of gap junctions [39] and reduction of pericytes [40]. In
our experiment, the calculated IDO activity did not differ from that in controls both in the
retina and in serum. However, this might be an effect of the measurement method or the
selected timepoints. For example, elevated IDO expression has been shown in the retina in
the course of diabetic retinopathy due to microglial activation [41]. Therefore, the elevation
of IDO activity might be present at some pathology stages in DBA/2J mice.
In contrast to other KP metabolites, levels of 3OH-K, a KP metabolite that is thought
to play a neurotoxic role in several pathologies [42], were elevated in the retina in 10-
month-old DBA/2J mice when compared to 6-month-old mice. Remarkably, we did
not observe a similar elevation of this metabolite in the serum. Conversion of KYN to
3OH-K is catalyzed by kynurenine 3-monooxygenase (KMO), an enzyme produced in the
nervous system in microglia [43]. Microglia activation was previously shown to be an
early event in the course of glaucomatous pathology in DBA/2J mice and to correlate with
the severity of neurodegeneration in these mice [44]. We have also recently shown that
KMO is overexpressed in two animal models of glaucoma: optic nerve crush and NMDA-
induced RGC loss [14]. Interestingly, the dynamics of changes differed in these two animal
models (peak expression 12 h after crush and 48 h after intravitreal NMDA administration).
3OH-K concentration, therefore, may correspond with pathological degenerative changes
observed in DBA/2J mice. In the 6th month, apoptosis peak was noticed, followed by
necrosis, Mueller glia cell activation, and angiogenesis [21]. These observations suggest
that KMO overexpression and activation could be a common mechanism in glaucomatous
neurodegeneration. Studying this mechanism is an interesting new direction since the data
on the role of KMO activation and overproduction of 3OH-K in retinal pathologies are
currently very scarce.
Besides ocular abnormalities, DBA/2J mice also display numerous other pathologies
such as hearing loss [45], susceptibility to audiogenic seizures [46], and calcified lesions [47].
At least some of these abnormalities may be related to TRP metabolism disturbances;
an example could be audiogenic seizures that were shown to be linked with abnormal
serotonin signaling in these mice [46]. Considering the number of pathologies and reduced
concentration of the KP metabolites in the serum, DBA/2J mice seem to be a good candidate
model for further experiments investigating these correlations.
Finally, modulating the TRP metabolism was postulated as a new therapeutic target
in multiple neurological diseases [48]. One promising approach is the development of
KP enzymes inhibitors. While IDO inhibitors have already reached clinical trials, they
are rather regarded as potential anti-cancer therapeutics; KMO inhibitors that could be
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of more interest as potential drugs in neurodegenerative diseases are still in the earlier
pre-clinical stage of development [49]. However, the data on the therapeutic modulation
of KP in retinal degeneration is still limited. A study by Harper et al. demonstrated
that administration of a KMO inhibitor Ro-61-8048 prevented retinal injury induced by
supersonic blast waves [50]. Another recent study by Nahomi et al. [15] demonstrated
that the absence of KMO is protective against RGCs in retinal ischemia-reperfusion injury
(induced by transient elevation of IOP). Moreover, they demonstrated the protective effect
of intravenous KYNA administration despite some reports suggesting low permeability of
the brain-blood barrier and possibly also blood-retina barrier to KYNA [38]. Our results
indicate that such an approach could also be promising in animal models of glaucoma
and, finally, as a therapeutic target for future clinical applications. Moreover, DBA/2J mice
could be an attractive animal model for studying such interventions’ therapeutic efficacy.
One limitation of the study is the relatively small number of animals included. How-
ever, it was possible to demonstrate statistically significant differences between the groups.
We have also decided to include only female mice, which allowed us to make the study
groups homogenous and reduce the number of animals required according to the 3R rule.
However, we cannot exclude the effect of sex on TRP metabolism. It would also be interest-
ing to track TRP metabolism alterations in older animals with very advanced glaucoma.
In the future, it would also be desirable to perform a direct measurement of IDO activity
that would allow a more definite conclusion on changes of IDO activity in the DBA/2J
glaucoma model.
The content of TRP recorded in our blood samples was low in comparison to data
from literature [51–53]. The reason for this discrepancy is unknown. It is well known
that quantification of TRP is a real challenge and different methods have been developed
and utilized. Thus, the use of different methods of sample preparation and tryptophan
detection might explain at least in part the differences between data reported by different
groups of researchers. However, we are convinced, that apart from the absolute values, the
comparison of data obtained under identical experimental conditions are conclusive.
Finally, it was not possible to perform a histological evaluation of the retinas that
underwent biochemical analysis. Therefore, we cannot directly confirm RGC degeneration
in all the DBA/2J mice included in the study. However, our previous results showed
alterations in ocular morphology and elevated IOP in virtually all 10-month-old animals
from the same population [27].
4. Materials and Methods
4.1. Animals
All experiments were performed according to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research and the European Communities Council
directive of 22 September 2010 (2010/63/EU). All the respective local regulations for
animal experiments were also obeyed, and the respective local ethics committee approved
the experiments (Warsaw IV Local Ethics Committee, approvals no. 88/2012, 94/2012,
11/2015).
The experiment was performed in female DBA/2J mice aged 6 and 10 months (model
of glaucoma, 5 animals per group) and female C57BL/6 mice of the same age (control mice,
5 animals per group) that were obtained from the breeding colony at the Mossakowski
Medical Research Centre Polish Academy of Sciences (MMRC). John et al. [26] have shown a
significant impact of sex on IOP in DBA/2J mice. In this study, the difference was significant
from the 6th month of age (13 mm Hg in females vs. 9.4 mm Hg in males) and was even
more pronounced in 9-month-old animals (20.3 mm Hg vs. 16.2 mm Hg). Therefore, we
chose to perform this experiment on females only as in our previous studies [22,27] to
make the groups more consistent in terms of IOP-related pathology.
Animals were provided a standardized diet and water ad libitum and were maintained
at 12–12 h light-dark cycle.
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4.2. Sample Collection
Animals were anesthetized with ketamine-xylazine injection (ip., 100 mg/kg body
weight and 10 mg/kg, respectively). Blood was collected from the right ventricle of the
heart after thoracotomy. Afterward, both eyeballs were extracted, and the death of the
animal was confirmed by cervical dislocation. Eyes underwent hemisection along the ora
serrata. The cornea, lens, and vitreous body were subsequently removed, and the retinas
were collected and immediately frozen in liquid nitrogen. Blood samples (0.7–1.0 mL)
were allowed to clot for 2 h and afterward centrifuged (10 min, 1100× g, 4 ◦C). The retina
and serum samples were stored at −80 ◦C until the determinations of KP metabolites
were performed.
4.3. Determination of Tryptophan and its Metabolites
One hundred microliters of blood samples were deproteinized with twenty microliters
of 6% M HClO4 and centrifuged at 12,000× g for 20 min at 4 ◦C.
TRP, KYN, and KYNA were measured with high-performance liquid chromatography
(HPLC) according to Zhao et al. (2010) with modifications [54]. The UltiMate 3000 analytical
HPLC system with UltiMate 3000 Autosampler with column compartment (Thermo Fisher
Scientific, Waltham, MA, United States) was used for the measurements. Chromatography
was carried out at 30 ◦C. The HPLC system was equipped with an analytical column
(Agilent HC-C18(2) column; 250 × 4.6 mm i.d.; 5 µm particle size, i.d. volume per injection
was 100 µL) was controlled by Chromeleon software. The mobile phase used for the
separation of the samples (20 mmol/L NaAc, 3 mmol/L ZnAc2, and 7% acetonitrile) was
pumped at a flow-rate of 1 mL/min; (the volume per injection was 100 µL). KYN and TRP
were detected with a UV detector (set for 365 nm and 250 nm, respectively). KYNA was
analyzed fluorometrically (excitation 344 nm, emission 398 nm).
3OH-K was analyzed using an electrochemical detector (The Thermo Scientific Dionex
UltiMate 3000 ECD-3000RS), connected to an analytical cell with the oxidation voltage set at
0.6 V, according to the method described by Heyes and Quearry [55]. Waters Spherisorb S3
ODS2 150 × 2.1 mm column (USA) was perfused with a mobile phase consisting of 2% ace-
tonitrile, 0.9% triethylamine, 0.59% phosphoric acid, 0.27 mM sodium EDTA, and 8.9 mM
heptane sulfonic acid (flow 0.3 mL/min; the volume per injection was 10 µL). Chromeleon
7.2 software was used to control HPLC systems and record the chromatographic data. IDO
activity was calculated as a KYN/TRP ratio.
The stock solutions of TRP and kynurenines were prepared by dissolving the relevant
amount of working standards in the mobile phase. The concentration of the standard was
equal to or greater than the maximum concentration to be found in samples. All stock
solutions were stored at 2–8 ◦C. The formula used for calculating the calibration curve
was the external standard method. The six-point linearity curve was prepared in three
replicates. Thermo Scientific Chromeleon Chromatography Data System automatically
determined the calibration curves for the external standards. For TRP and kynurenines
quantification, the reference calibration curves were used. TRP and kynurenines were
identified based on their retention times (TRP 12.2 ± 0.3 min; L-KYN 6.4 ± 0.3 min; KYNA
11.2 ± 0.2 min; and 3OH-K 6.8 ± 0.4 min).
The concentrations were calculated by comparing the peak area of the sample with
the same area of the standard used commercially. In order to evaluate the HPLC method,
every 1 out of 10 samples was chosen at random and spiked with known concentrations of
mixed standards in duplicate. For the calculation of the recovery percentage, we used the
following equation: % recovery = 100 × (measured value for spiked samples − measured
value for unspiked samples)/known value of the mixed standards. The results include
samples which recovery percentage is in the range from 80% to 120%.
4.4. Visualization of the Neural Retina and Ocular Morphology with Magnetic Resonance Imaging
The neural retina was visualized, as we described previously [27]. In brief, the animals
received an intraperitoneal injection of 0.1 mol/L manganese chloride solution and were
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subjected to magnetic resonance imaging (MRI) after 24 h. Imaging was performed with
7T MR tomograph (BioSpec 70/30USR Bruker, Ettlingen, Germany) equipped with 86 mm
(inner diameter) transmit coil and 10 mm planar receive-only surface coil. The imaging
sequence used was T1-weighted FLASH 3D (TR/TE = 48/4 ms, NA = 5, FA = 25◦, spatial
resolution 68 µm × 68 µm × 68 µm, scan time 28min). This imaging protocol also allowed
us to visualize ocular morphology in these mice.
4.5. Statistical Analysis
Shapiro–Wilk test was applied for normality, followed by a nonparametric Mann–Whitney
test or parametric Student’s t-test by a normal distribution. Differences were considered
statistically significant for p < 0.05. Data are presented as mean ± standard deviation.
5. Conclusions
In conclusion, according to our results, the TRP metabolism alterations in the retina of
DBA/2J mice seem to reflect systemic alterations in TRP metabolism. Moreover, DBA/2J
mice could be an attractive model for studying TRP metabolism alterations’ effects.
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